Adagene (NASDAQ:ADAG) Upgraded at Wall Street Zen

Adagene logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Adagene from “sell” to “hold.” Other analyst views are mixed, though MarketBeat reports a “Moderate Buy” consensus rating and an average price target of $8.25.
  • Adagene shares opened at $1.76, below their 50-day moving average of $2.55 and 200-day moving average of $3.38; the stock’s 52-week range is $1.27–$4.85.
  • CEO Peter Luo bought 20,290 shares at an average price of $3.15, increasing his stake by 29.73%. Insiders own 21.20% of the company.
  • Five stocks we like better than Adagene.

Adagene (NASDAQ:ADAG - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday, Wall Street Zen reports.

A number of other analysts have also recently weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Adagene in a report on Thursday, October 15th. Stifel Nicolaus set a $7.00 price objective on Adagene in a research report on Monday, October 19th. HC Wainwright reissued a "buy" rating and issued a $7.00 price target on shares of Adagene in a report on Monday, October 19th. Finally, Chardan Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Adagene in a research note on Wednesday, October 28th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $8.25.

Read Our Latest Analysis on Adagene

Adagene Price Performance

Shares of ADAG stock opened at $1.76 on Friday. The company's 50 day moving average is $2.55 and its 200 day moving average is $3.38. Adagene has a 52-week low of $1.27 and a 52-week high of $4.85.

Insider Activity

In other news, CEO Peter Luo purchased 20,290 shares of the stock in a transaction dated Wednesday, September 16th. The shares were purchased at an average price of $3.15 per share, with a total value of $63,913.50. Following the transaction, the chief executive officer owned 88,535 shares in the company, valued at $278,885.25. The trade was a 29.73% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 21.20% of the stock is owned by company insiders.

Institutional Trading of Adagene

Hedge funds and other institutional investors have recently modified their holdings of the business. Flputnam Investment Management Co. acquired a new position in shares of Adagene in the third quarter worth $2,183,000. Marshall Wace LLP boosted its position in Adagene by 554.6% during the third quarter. Marshall Wace LLP now owns 452,310 shares of the company's stock worth $1,447,000 after purchasing an additional 383,210 shares in the last quarter. State Street Corp purchased a new stake in shares of Adagene in the third quarter valued at $88,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Adagene during the first quarter worth $135,000. 9.51% of the stock is owned by institutional investors and hedge funds.

About Adagene

(Get Free Report)

Adagene Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based cancer immunotherapies. Its research combines computational protein-design methods with antibody engineering to create treatments intended to target tumors and engage the immune system. The company's technologies include its SAFEbody platform, which is designed to keep an antibody's activity masked until it reaches the tumor environment. Adagene is also developing antibody candidates that target immune-regulatory pathways, including CTLA-4, for potential use in cancer treatment.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Adagene Right Now?

Before you consider Adagene, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adagene wasn't on the list.

While Adagene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines